Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC

被引：0

作者：

Simpson, Iain ^{[1
]}

Anderton, Mark J. ^{[1
]}

Andrews, David M. ^{[1
]}

Breed, Jason ^{[1
]}

Davies, Emma ^{[1
]}

Debreczeni, Judit E. ^{[1
]}

Flemington, Vikki ^{[1
]}

Gibbons, Francis D. ^{[2
]}

Graham, Mark A. ^{[1
]}

Hopcroft, Philip ^{[1
]}

Howard, Tina ^{[1
]}

Hudson, Julian ^{[1
]}

Jones, Clifford D. ^{[1
]}

Jones, Christopher ^{[1
]}

Lindsay, Nicola ^{[1
]}

Pease, J. Elizabeth ^{[1
]}

Rawlins, Philip ^{[1
]}

Roberts, Karen ^{[1
]}

Swallow, Steve ^{[1
]}

St-Gallay, Steve ^{[1
]}

Tonge, Michael E. ^{[1
]}

Ward, Richard A. ^{[1
]}

机构：

[1] AstraZeneca, Cambridge, England

[2] AstraZeneca, Boston, MA USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-1647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1647

引用

页数：3

共 50 条

[31] Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
Luecking, Ulrich
Wortmann, Lars
Wengner, Antje M.
Lefranc, Julien
Lienau, Philip
Briem, Hans
Siemeister, Gerhard
Boemer, Ulf
Denner, Karsten
Schaefer, Martina
Koppitz, Marcus
Eis, Knut
Bartels, Florian
Bader, Benjamin
Bone, Wilhelm
Moosmayer, Dieter
Holton, Simon J.
Eberspaecher, Uwe
Grudzinska-Goebel, Joanna
Schatz, Christoph
Deeg, Gesa
Mumberg, Dominik
von Nussbaum, Franz
JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (13) : 7293 - 7325
[32] BLU-222, a potent and highly selective CDK2 inhibitor, demonstrates antitumor activity as monotherapy and as combination treatment in CCNE1-aberrant endometrial cancer models
House, Nealia
Brown, Victoria
Yuan, Liang
Chen, Maxine
Lee, Stephanie
Wu, Rentian
Muthuswamy, Lakshmi
Ribich, Scott
Ramsden, Philip
Faia, Kerrie
CANCER RESEARCH, 2024, 84 (06)
[33] Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy
Sun, Qiaoling
Zhou, Jinghong
Zhang, Zheng
Guo, Mingchuan
Liang, Junqing
Zhou, Feng
Long, Jingwen
Zhang, Wei
Yin, Fang
Cai, Huaqing
Yang, Haibin
Zhang, Weihan
Gu, Yi
Ni, Liang
Sai, Yang
Cui, Yumin
Zhang, Meifang
Hong, Minhua
Sun, Junen
Yang, Zheng
Qing, Weiguo
Su, Weiguo
Ren, Yongxin
CANCER BIOLOGY & THERAPY, 2014, 15 (12) : 1635 - 1645
[34] eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade
Webster, Kevin R.
Goel, Vikas K.
Staunton, Jocelyn
Hung, Ivy N. J.
Parker, Gregory S.
Stumpf, Craig R.
Molter, Jolene
Chiang, Gary G.
Wegerski, Christopher J.
Sperry, Samuel
Chen, Joan
Huang, Vera
Thompson, Peggy A.
Tran, Chinh
Ernst, Justin T.
Webber, Stephen E.
Sprengeler, Paul A.
Reich, Siegfried H.
CANCER RESEARCH, 2017, 77
[35] Discovery of CC-91516, a potent and selective ERK/NLK inhibitor, with anti-tumor activity in preclinical cancer models harboring BRAF or CTNNB1 mutation
Xu, Shuichan
Tran, Tam
Zhu, Dan
Shi, Tao
Mikolon, David
Leisten, Jim
Chamberlain, Philip
LeBrun, Laurie
Bahmanyar, Sogole
Jiang, Ning
Zhao, Jingjing
Malek, Mehnaz
Filvaroff, Ellen
Raymon, Heather
Hubbard, Robert
Boylan, John
CANCER RESEARCH, 2022, 82 (12)
[36] BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
Patel, Manish R.
Juric, Dejan
Henick, Brian S.
Duska, Linda R.
Wu, Rentian
Guo, Jian
Zhang, Hui
Newberry, Kate
Rinne, Mikael
Yap, Timothy A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] ASN007, an oral ERK1/2 inhibitor, shows strong antitumor activity across a panel of KRAS subtype mutant cancer models.
Reddy, Sanjeeva P.
Thompson, Scott K.
Usansky, Helen
Smith, Roger A.
Denis, Louis
Gupta, Sandeeep
MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 56 - 57
[38] Strong antitumor activity of ASN007, an oral ERK1/2 inhibitor, in PDX tumor models with MAP kinase pathway alterations including KRAS mutations
Reddy, Sanjeeva P.
Rao, Niranjan S.
Smith, Roger A.
Thompson, Scott K.
Toker, Sarper
CANCER RESEARCH, 2018, 78 (13)
[39] The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
Herencia-Ropero, Andrea
Llop-Guevara, Alba
Staniszewska, Anna D.
Domenech-Vivo, Joanna
Garcia-Galea, Eduardo
Moles-Fernandez, Alejandro
Pedretti, Flaminia
Domenech, Heura
Rodriguez, Olga
Guzman, Marta
Arenas, Enrique J.
Verdaguer, Helena
Calero-Nieto, Fernando J.
Talbot, Sara
Tobalina, Luis
Leo, Elisabetta
Lau, Alan
Nuciforo, Paolo
Dienstmann, Rodrigo
Macarulla, Teresa
Arribas, Joaquin
Diez, Orland
Gutierrez-Enriquez, Sara
Forment, Josep V.
O'Connor, Mark J.
Albertella, Mark
Balmana, Judith
Serra, Violeta
GENOME MEDICINE, 2024, 16 (01):
[40] Activity of AZD4547, a potent and selective FGF-receptor inhibitor, alone and in combination with chemotherapy in standard xenograft and human primary explant models of FGF-receptor 2 amplified gastric cancer
Zhang, Jingchuan
Zhang, Lin
Yin, XiaoLu
Xu, YanPing
Su, Xinying
Liu, Kunji
Li, Ming
Smith, Paul D.
Kilgour, Elaine
Brooks, A. Nigel
Gayine, Paul R.
CANCER RESEARCH, 2012, 72

← 1 2 3 4 5 →